Evaluation of serum cardiac troponin I and N‐terminal pro‐B‐type natriuretic peptide levels in patients with alopecia areata

Marie, Radwa El‐Sayed Mahmoud; Elsayed, Galal; Attia, Fadia M.; Gomaa, Amal H. A.

doi:10.1111/ced.14425

Cited by 10 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2020) in Egyptian patients reported significantly elevated levels of cardiac troponin I and N-terminal pro-B-type natriuretic peptide biomarkers in patients with AA compared with controls. The study suggested a possible association of AA with myocardial inflammation and an increased risk of developing cardiovascular disease [ 48 ].…”

Section: Resultsmentioning

confidence: 99%

Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs

Al Hammadi,

Parmar,

Aljefri

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Background Alopecia areata (AA) is an autoimmune disease characterized by non-scarring hair loss in adults and children. Clinical manifestations range from hair loss in small, well-circumscribed patches to total hair loss on the scalp or any other hair-bearing areas. Although the exact pathogenesis of AA is not fully understood, it is thought that loss of immune privilege caused by immunological dysregulation of the hair follicle is key. Genetic susceptibility also plays a role. Response to currently available treatments is widely variable, causing patient dissatisfaction and creating an unmet need. AA is frequently associated with multiple comorbidities, further affecting patient quality of life. Aims and Findings AA causes a significant burden on dermatologists and healthcare systems in the Middle East and Africa. There is a lack of data registries, local consensus, and treatment guidelines in the region. Limited public awareness, availability of treatments, and patient support need to be addressed to improve disease management in the region. A literature review was conducted to identify relevant publications and highlight regional data on prevalence rates, diagnosis, quality of life, treatment modalities, and unmet needs for AA in the Middle East and Africa.

show abstract

Section: Resultsmentioning

confidence: 99%

Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs

Al Hammadi,

Parmar,

Aljefri

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…On the other hand, recently, in alopecia areata, literature data show a tendency to thrombosis and an increased risk of heart attack and stroke. In addition, studies have found elevated levels of cardiac biomarker troponin I and congestive heart disease biomarker BNP in patients with alopecia areata [ 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

The Role of Ischemia-modified Albumin and Ischemia-modified Albumin to Albumin Ratios in Patients with Alopecia Areata

TanaCan

Öztekin

Savcı

et al. 2023

Dermatol Pract Concept

View full text Add to dashboard Cite

Objective: To investigate the role of ischemia-modified albumin (IMA) and IMA/albumin levels in patients with AA. Methods: The present prospective crossectional study includes patients ≥ 18 who admitted to the Dermatology and Venerology Department of XXXX University Hospital between April 1 2021, and September 30 2021. 70 patients participated in the study (n=34 for the study group and n=36 for the control group). Demographic features, clinical characteristics, IMA, and IMA/albumin levels were compared between the groups. Study group was divided into subgroups based on the number of patches, disease duration, and number of disease attacks. IMA and IMA/albumin levels were compared between each subgroup. Results: Study and control groups were similar with regard to demographic features and clinical characteristics. Significant differences were observed between the mean IMA and IMA /albumin ratio (p=0.004 and 0.012, respectively). The study subgroups were comparable for the number of patches, disease duration and number of disease attack. Conclusion: Although oxydative stress is an important component in the etiology of AA, IMA and IMA/albumin may not be useful in the prediction of disease severity in patients with AA. Keywords: Alopecia areata, ischemia-modified albumin, IMA/albumin, disease severity.

show abstract

“…AA is an inflammatory form of nonscarring alopecia, which can affect any hair-bearing area. 42 Clinical presentations can include the sudden onset of round alopecic patches to total scalp and body hair loss, known as alopecia totalis and universalis, respectively. 43,44 AA affects both men and women of all ages, with an estimated lifetime risk of 2.1% in the general population.…”

Section: Aamentioning

confidence: 99%

“…57 Further supporting this finding, a case-control study found that serum levels of cTnI (mean difference = 48.77; 95% CI: 46.2-51.33) and N-terminal pro-B-type natriuretic peptide (NT proBNP) (mean difference = 30.87; 95% CI: 28.41-33.33) were significantly higher in patients with AA compared to controls (cTnI t(86) = 37.79; p < 0.001, NT proBNP t(86) = 24.97; p < 0.001). 42 Although many studies have reported a correlation between AA and CVD risk, there have been a few studies that potentially counter this claim. In a retrospective study of 1377 patients with AA over a 10-year period, Huang et al found patients with AA had decreased odds of developing stroke (OR: 0.39; 95% CI: 0.18-0.87) and a trend towards decreased AMI (OR: 0.91; 95% CI: 0.59-1.39).…”

Section: Aamentioning

confidence: 99%

“…Shoeib et al confirmed the same finding of elevated cTnI levels with their study, however, they compared patients with AA to patients with female AGA and controls without alopecia 57 . Further supporting this finding, a case–control study found that serum levels of cTnI (mean difference = 48.77; 95% CI: 46.2–51.33) and N‐terminal pro‐B‐type natriuretic peptide (NT proBNP) (mean difference = 30.87; 95% CI: 28.41–33.33) were significantly higher in patients with AA compared to controls (cTnI t (86) = 37.79; p < 0.001, NT proBNP t (86) = 24.97; p < 0.001) 42 …”

Section: Nonscarring Alopeciasmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular risk in patients with scarring and nonscarring alopecias: Assessing the current state of evidence

Sally,

Robinson,

Orlow

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

Alopecia is traditionally classified into scarring and nonscarring subtypes, with etiopathologies ranging from androgen‐mediated to immuno‐inflammatory. Over 50% of men and almost 50% of women will experience some form of hair loss in their lifetime. Given this prevalence and the psychosocial significance of hair, understanding the pathophysiology and comorbidities of different types of hair loss is imperative. Other proinflammatory dermatologic disorders, such as psoriasis, are recognised to have systemic manifestations including an increased risk of cardiovascular (CV) disease, and are now considered CV risk‐enhancing conditions. With increased recognition of the importance of systemic inflammation in promoting atherosclerosis, high prevalence, and improved treatment strategies, there is increased interest in establishing whether a similar association between alopecia and cardiovascular disease (CVD) exists. In this manuscript, we aim to review the current literature regarding CV risk in androgenic alopecia (AGA) and alopecia areata (AA). Additionally, we review the literature for cicatricial alopecias and highlight the need for more research into their potential associations with CV risk. Evidence from the identified AGA publications suggests an association of AGA with CV risk factors including hypertension, dyslipidemia, and insulin resistance, as well as with coronary artery disease. For AA, most of the identified studies found an association between AA and CV risk, though the relationships were not always statistically significant. Research on cicatricial alopecias and CV risk is limited and often contradictory. There is great need for more studies regarding the association between various types of alopecia and the development of CVD, and potential mechanisms. Particularly needed are more studies of cicatricial alopecias and potential associated CV risk. While some literature suggests that patients with alopecia have an increased risk of CVD, the lack of concrete evidence represents a notable gap in our current understanding.

show abstract

Evaluation of serum cardiac troponin I and N‐terminal pro‐B‐type natriuretic peptide levels in patients with alopecia areata

Cited by 10 publications

References 9 publications

Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs

Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs

The Role of Ischemia-modified Albumin and Ischemia-modified Albumin to Albumin Ratios in Patients with Alopecia Areata

Cardiovascular risk in patients with scarring and nonscarring alopecias: Assessing the current state of evidence

Contact Info

Product

Resources

About